Skip to main content

Linagliptin_Metformin

02-03-2023 | Empagliflozin | News

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

11-24-2020 | Older adults | News

Age has no impact on CV outcomes with linagliptin vs glimepiride

Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

09-24-2020 | EASD 2020 | Conference coverage | News

GLIMLINA: Glimepiride–linagliptin combination shows potential for HNF1A-MODY

Adding linagliptin to glimepiride treatment reduces some measures of glycemic variability and improves glycemic control in patients with HNF1A-MODY, indicate findings from the GLIMLINA trial.

08-16-2019 | Linagliptin | News

Add-on linagliptin improves glycemic control in older people with type 2 diabetes

The addition of linagliptin to stable insulin treatment improves glycemic control without increasing the risk for clinically important hypoglycemia among older individuals with type 2 diabetes, randomized trial findings suggest.

06-12-2019 | DPP-4 inhibitors | ADA 2019 | News

CARMELINA findings confirmed in highest CV risk subgroups

Secondary data from the CARMELINA trial, presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, confirm the positive primary cardiovascular and renal safety findings, this time in particularly high-risk patients.

06-11-2019 | Linagliptin | ADA 2019 | News

CAROLINA shows neutral cardiovascular profile for modern sulfonylurea

The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.

11-28-2018 | Linagliptin | News

Linagliptin preferable to insulin in majority of surgical type 2 diabetes patients

Daily linagliptin is effective and reduces hypoglycemia risk relative to multidose insulin in type 2 diabetes patients with mild-to-moderate hyperglycemia who are undergoing non-cardiac surgery, suggest the results of a randomized controlled study.

10-05-2018 | Linagliptin | EASD 2018 | News

Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes

Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.